PTK2 and epithelioid sarcoma: Furthermore, aurora kinase B (AURKB) inhibitors have been identified as a synergistic drug in combination with FAK inhibitors by utilizing high-throughput drug combination screening, with AURKB highly expressed in ES patients and ES cells.